OraVax, Inc.
10Patents
0Active
10Granted
32Portfolio score
Filing activity: Oct 5, 1993 → Oct 20, 1998
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6214341A | Passive immunization against Clostridium difficile disease | Human Necessities | 59 | Expired |
| US5690938A | Oral immunization with multiple particulate antigen delivery system | Chemistry; Metallurgy | 37 | Expired |
| US5538729A | Oral treatment of helicobacter infection | Human Necessities | 35 | Expired |
| US5919463A | Clostridium difficle toxins as mucosal adjuvants | Emerging Cross-Sectional Technologies | 34 | Expired |
| US5534411A | Monoclonal IgA antibody specific for respiratory syncytial virus, a hybridoma cell line that produces this antibody amd methods of using the antibody to diagnose RSV infection | Human Necessities | 33 | Expired |
| US6290962A | Urease-based vaccine and treatment for helicobacter infection | Emerging Cross-Sectional Technologies | 14 | Expired |
| US5733740A | Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma | Physics | 9 | Expired |
| US6258529A | PCR amplification of rearranged genomic variable regions of immunoglobulin genes | Chemistry; Metallurgy | 5 | Expired |
| US5686270A | Production of antigens by self-assembly of polypeptide components | Emerging Cross-Sectional Technologies | 3 | Expired |
| US5833995A | Use of bluetongue virus proteins as vaccine components | Emerging Cross-Sectional Technologies | 1 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.